Law Offices of Thomas J. Lamb

  • About Firm
  • Practice Areas
  • Free Case Evaluation
  • Quick Contact Form
  • Frequently Asked Questions
  • Attorney Tom Lamb

Beovu Label Change: Novartis Adds Information, Increases Safety Warnings in February 2022

February 25, 2022 By Law Offices of Thomas J. Lamb, P.A.

We had been watching for a second Beovu label change since May 2021, when Novartis stopped three Beovu clinical trials for safety reasons, and, at the same time, said it would update the Beovu drug label. Finally, in February 2022, Novartis added information and increased safety warnings about various Beovu eye-related side effects, such as retinal … [Read more...]

Filed Under: Unsafe Drugs Tagged With: Beovu, blindness, retinal vascular occlusion, retinal vasculitis, vision loss

Beovu Drug Label Revised December 2021 Was Issued in Europe, But Not in the US

January 22, 2022 By Law Offices of Thomas J. Lamb, P.A.

A “new” Beovu drug label which was revised in December 2021 sets forth some additional information about the vision-related Beovu side effects intraocular inflammation, retinal vasculitis, and retinal vascular occlusion. We point out, however, that there was no similar 2021 Beovu label change issued by Novartis in the US. From this Drug Safety … [Read more...]

Filed Under: Unsafe Drugs Tagged With: Beovu, intraocular inflammation, occlusive retinal vasculitis, retinal vascular occlusion, retinal vasculitis, vision loss

Beovu: Rates of Intraocular Inflammation and Retinal Vascular Occlusion

December 22, 2021 By Law Offices of Thomas J. Lamb, P.A.

A November 2021 article published by the medical journal JAMA Ophthalmology, “Safety Outcomes of Brolucizumab in Neovascular Age-Related Macular Degeneration”, provides new information about the incidence rates of intraocular inflammation and retinal vascular occlusion associated with Beovu (brolucizumab). This is our 19th article about Beovu … [Read more...]

Filed Under: Unsafe Drugs Tagged With: Beovu, intraocular inflammation, retinal vascular occlusion, vision loss

Some Information About Our Monthly Law Firm Newsletter

March 8, 2021 By Law Offices of Thomas J. Lamb, P.A.

The Lamb Law Office Newsletter is a monthly communication from our law firm to help keep you up to date with some of the cases that we are working on for clients at the present time. In addition, we provide at least one information resource item per month, which you or someone you know might find helpful from time to time. Past … [Read more...]

Filed Under: Uncategorized Tagged With: Asbestos Mesothelioma, Belviq, benzene, Beovu, breast implants, Elmiron, genx, Injectafer, Lamb Law Office Newsletter, Law Firm Newsletter, Monthly Newsletter, Newsletter, sglt2 inhibitors, Xeljanz

Find What You Want Here

Get Free Case Evaluation

We encourage you to submit an online Case Evaluation Form – it is confidential and there is no obligation.

Or call our toll-free number, 800-426-9535, to speak directly to attorney Tom Lamb about your possible case.

Feel Free To Contact Us

Quick Contact Form
 
Send an Email to Tom Lamb

(800) 426-9535

Main Navigation Menu

  • About Firm
  • Asbestos-Mesothelioma Cases
  • Benzene Disease Claims
  • Drug Injury Lawsuits
  • Breast Implant Cancer Cases
  • Case Evaluation Menu
  • Quick Contact Form
  • Frequently Asked Questions
  • Medical Records Charges
  • Collection of Articles
  • Sitemap

Lamb Law Office Newsletter

Lamb Law Office Newsletter provides periodic updates about some of the cases that we are working on for clients, as well as an information resource you might find helpful.

Subscribe using Form below.

Subscription Form

* indicates required

Our Other Websites

DrugInjuryLaw.com

DrugInjuryWatch.com

Asbestos-Mesothelioma.com

Contact Information

Law Offices of Thomas J. Lamb, P.A.
1908 Eastwood Road, Suite 225
Wilmington, North Carolina 28403
910-256-2971 | 800-426-9535
TJL@LambLawOffice.com

  • Home
  • Disclaimer and Copyright Notices
  • Sitemap

Copyright © 2025 · Law Offices of Thomas J. Lamb, P.A.